What is Theolytics?
Theolytics is a prominent biotechnology company headquartered in England, dedicated to the advancement of oncolytic immunotherapy for the treatment of solid tumors, with a particular focus on ovarian cancer. Leveraging its proprietary ADENOVO discovery platform, the company engineers viruses to create highly targeted therapies designed to revolutionize patient care. Theolytics integrates deep expertise across virology, cancer biology, and immunology, fostering strategic alliances with leading biopharmaceutical entities and attracting investment from notable venture capital firms. Their commitment lies in making transformative therapies accessible, aiming for durable cures.
How much funding has Theolytics raised?
Theolytics has raised a total of $6.8M across 1 funding round:
Series A
$6.8M
Series A (2021): $6.8M with participation from Epidarex Capital, Oxford Sciences Enterprises, and TAIHO VENTURES , LLC
Key Investors in Theolytics
Epidarex Capital
Epidarex Capital is a transatlantic venture capital firm that focuses on building breakthrough life science companies in emerging hubs. They act as trusted partners to founders and co-investors, utilizing deep scientific and industry networks to create value.
Oxford Sciences Enterprises
Oxford Science Enterprises is an independent investment company created to found, fund, and build transformational businesses through its unique partnership with the University of Oxford, a leading research university.
TAIHO VENTURES , LLC
Undisclosed investor participating in the funding round.
What's next for Theolytics?
With the recent major strategic investment, Theolytics is poised for significant expansion and acceleration of its research and development initiatives. This capital infusion is expected to fuel the progression of its ADENOVO platform and pipeline candidates through critical clinical milestones. The company's focus on solid tumors, especially ovarian cancer, positions it within a high-need area of oncology. Future endeavors will likely involve scaling operations, expanding its scientific team, and forging further partnerships to expedite the path to market for its innovative immunotherapies, solidifying its role as a key player in the biotech landscape.
See full Theolytics company page
